Xolair 150 MG/ML autoinjectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FCZJ2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $10,484.64 by the Defense Logistics Agency on January 27, 2026, for the supply of Xolair 150 mg/ml autoinjector. This firm fixed-price delivery order, with an ultimate completion date of February 18, 2026, carries no set-aside designation, indicating the company competed on an unrestricted basis. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499,999,999 contract awarded in November 2025 that positions the company as a regional prime vendor for comprehensive pharmaceutical support to Department of Defense military healthcare facilities.
The PPV-G GEN V program represents a key component of the DLA's broader $30.3 billion pharmaceutical acquisition strategy, structured to provide firm fixed-price delivery orders for branded and generic prescription drugs, biologics, and medical consumables to support recurring medical supply needs across military healthcare operations worldwide. DMS Pharmaceutical Group's established performance on numerous prior delivery orders demonstrates its capability to fulfill specialized pharmaceutical requirements within the federal military medical system, with this Xolair delivery contributing to the company's continued role as a critical supplier within the defense pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FCZJ2?
SPE2DR26FCZJ2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FCZJ2 worth?
The government has obligated $10,485 on SPE2DR26FCZJ2.
Is contract SPE2DR26FCZJ2 an order under another contract?
Yes. SPE2DR26FCZJ2 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZJ2 competed?
The extent of competition for SPE2DR26FCZJ2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award